Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page